Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2266 • ACR Convergence 2025
Impact of Rheumatoid Arthritis Therapeutic Classes on Risk of All-Cause Mortality and All-Cause Cancer: A Population-Based Cohort Study
Mohammad Movahedi¹, Angela Cesta¹, Sibel Aydin², Pooneh Akhavan³, Tetyana Kendzerska⁴, Claire Bombardier¹ and Bindee Kuriya⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ³self-employed, Toronto, ON, Canada, ⁴Ottawa Hospital Research Institute, Mississuaga, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Observational studies on RA therapeutic classes have shown conflicting results on their impact on mortality and cancer. When analyzing long-term outcomes, it is essential…
Abstract Number: 2250 • ACR Convergence 2025
Clinical and Serological Predictors of Interstitial Lung Disease in Rheumatoid Arthritis: Are Anti-Citrullinated Protein Antibodies Truly Relevant?
Martí Aguilar-Coll¹, Javier Narváez², Montserrat Roig Kim¹, Laia De Daniel Bisbe¹, Pol Maymó-Paituvi¹, Judith Palacios-Olid¹ and Joan Miquel Nolla¹, ¹Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ²Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Evidence on which risk factors predict the development of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) is scarce and of low…
Abstract Number: 2233 • ACR Convergence 2025
Spatial Multi-omics Demonstrates Shared Immune States Across Autoimmune Diseases and Target Tissues in the Accelerating Medicines Partnership: Autoimmune and Immune-Mediated Diseases Network (AMP AIM)
Caleb Marlin¹, Roopa Madhu², Erin Theisen³, Liz Bradshaw⁴, Ce Gao⁵, Thomas Eisenhaure⁶, Nicolas Sugiarto⁷, Accelerating Medicines Partnertship: Autoimmune and Immune Mediated Diseases⁸, Jill Buyon⁹, Michelle Petri¹⁰, Brad Rovin¹¹, Victoria Werth¹², Ellen M. Gravallese¹³, Jennifer Anolik¹⁴, Larry Moreland¹⁵, Laura Donlin¹⁶, Christopher Ritchlin¹⁷, Jose Scher¹⁸, Johann Gudjonsson¹⁹, Wilson Liao²⁰, Alexis Ogdie²¹, Caroline Shiboski²², A. Darise Farris¹, Alan Baer²³, Blake M. Warner²⁴, Jose Clemente²⁵, Adriana Heguy²⁶, Michael Brenner²⁷, Nir Hacohen²⁸, Joel Guthridge¹, Judith James¹, Soumya Raychaudhuri²⁹, Lam Tsoi¹⁹, Xiang Zhou³⁰, Joshua Welch³⁰, Rachael Clark³, ilya Korsunsky²⁹, Christopher Lessard¹ and Kevin Wei³¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Brigham and Women's Hospital, Brookline, MA, ³Brigham and Women's Hospital, Boston, ⁴Oklahoma Medical Research Foundation, Oklahoma City, ⁵Division of Rheumatology, Inflammation and Immunity, DOM, BWH; Harvard Medical School, Boston, MA, ⁶Broad Institute, Cambridge, MA, ⁷Broad Institute, Boston, ⁸Multiple Institutions, Oklahoma City, ⁹NYU Grossman School of Medicine, New York, NY, ¹⁰Johns Hopkins University School of Medicine, Timonium, MD, ¹¹The Ohio State University, Columbus, OH, ¹²University of Pennsylvania, Wynnewood, PA, ¹³Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA, ¹⁴University of Rochester Medical Center, Rochester, NY, ¹⁵University of Colorado, Denver, CO, ¹⁶Hospital for Special Surgery, New York, NY, ¹⁷University of Rochester Medical Center, Canandaigua, NY, ¹⁸New York University School of Medicine, New York, NY, ¹⁹University of Michigan, Ann Arbor, MI, ²⁰UCSF, San Francisco, CA, ²¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ²²University of California San Francisco, San Francisco, CA, ²³Johns Hopkins University School of Medicine, Baltimore, MD, ²⁴National Institutes of Health, Bethesda, MD, ²⁵Icahn School of Medicine at Mount Sinai, New York, NY, ²⁶NYU Grossman School of Medicine, New York, ²⁷Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ²⁸Broad Institute of MIT Harvard, Cambridge, MA, ²⁹Brigham and Women's Hospital, Boston, MA, ³⁰University of Michigan, Ann Arbor, ³¹Brigham and Women's Hospital at Harvard Medical School, Boston, MA
Background/Purpose: Autoimmune diseases affect more than 23.5 million Americans involving nearly every organ system of the human body. To identify shared, unique, and novel pathways…
Abstract Number: 2036 • ACR Convergence 2025
JAK1 selective inhibitors versus pan-JAK inhibitors: comparative real-world study of drug retention in chronic inflammatory arthritis
LETICIA LEON¹, Pedro Pablo Bermejo², Leonor Laredo³, José Alberto Peña⁴, María Teresa Benítez⁵, DALIFER FREITES⁶, CLARA DE MIGUEL³ and lydia Abasolo Alcazar⁷, ¹Fundación Investigación Biomédica Hospital Clínico San Carlos, IdISSC; Universidad Camilo Jose Cela, MADRID, Madrid, Spain, ²Clinical Pharmacology Service, San Carlos Clinical Hospital, MADRID, Madrid, Spain, ³Hospital Clinico San Carlos, MADRID, Madrid, Spain, ⁴Pharmacy Service San Carlos Clinical Hospital, MADRID, Madrid, Spain, ⁵San Carlos Clinical Hospital, MADRID, Madrid, Spain, ⁶Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ⁷IdISSC. HCSC, Madrid, Madrid, Spain
Background/Purpose: Janus kinase inhibitors (JAKis) are effective therapeutic agents against chronic inflammatory arthritis (CIA). Tofacitinib and baricitinib were defined as pan-JAK inhibitors, while upadacitinib and…
Abstract Number: 1921 • ACR Convergence 2025
Re-escalation of Treatment in Older Adults with Rheumatoid Arthritis After Anti-TNF Therapy De-escalation
Jiha Lee¹, Jonathan Martindale², Una Makris³ and Julie Bynum², ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, ³UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: Older adults with rheumatoid arthritis (RA) treated with biologic disease-modifying antirheumatic drugs (bDMARDs), including anti-TNFs, are at an increased risk of adverse effects. Current…
Abstract Number: 1748 • ACR Convergence 2025
Effect of Air Pollution on Disease Activity in Patients with Rheumatoid Arthritis
Sung Cheol Jung¹, Jeffrey Curtis², Seojin Yang³, Min Hyuk Lim⁴, Saram Lee⁵, Sung Ik Cho⁶, Jin Kyun Park⁷ and Eun Bong Lee⁶, ¹Seoul National University College of Medicine, Seoul, Republic of Korea, ²University of Alabama at Birmingham, Birmingham, AL, ³Seoul National University, Seoul, Republic of Korea, ⁴Ulsan National Institute of Science and Technology (UNIST), Ulsan, Republic of Korea, ⁵Seoul National University Hospital, Seoul, Republic of Korea, ⁶Seoul National University Hospital, Seoul, South Korea, ⁷Seoul National University College of Medicine, Jongno-gu, Seoul, South Korea
Background/Purpose: While air pollution has been implicated in the pathogenesis of rheumatoid arthritis (RA), its association with RA disease activity remains insufficiently investigated (1, 2).…
Abstract Number: 1675 • ACR Convergence 2025
Neuroimmune modulation in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors (TNFi)
Guillermo Valenzuela¹, Jane Box², Angela Crowley³, Joshua June⁴, Pendleton Wickersham⁵, Jeff Peterson⁶, Michael Thakor⁷, Susan Kim⁸, Tina Shah⁹, David Chernoff¹⁰ and John Tesser¹¹, ¹Integral Rheumatology & Immunology Specialists, Plantation, FL, ²DJL Clinical Research, PLLC, Charlotte, NC, ³Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, ⁴Great Lakes Center of Rheumatology, Lansing, MI, ⁵Arthritis Associates PA, San Antonio, TX, ⁶Western Washington Arthritis Clinic, Seattle, WA, ⁷arthritis and rheumatology, Fort Collins, CO, ⁸Lehigh Valley Hospital Network, Allentown, PA, ⁹Kansas City Physician Partners, Kansas City, MO, ¹⁰SetPoint Medical, Sausalito, CA, ¹¹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ
Background/Purpose: A substantial number of patients with rheumatoid arthritis (RA) experience treatment failure, incomplete response, or intolerance to TNFis (TNFi-IR). Neuroimmune modulation using an implantable…
Abstract Number: 1371 • ACR Convergence 2025
Effect of bDMARDs and tsDMARDS on diffuse interstitial lung disease associated with rheumatoid arthritis: systematic review and meta-analysis
Stéphane HILLIQUIN¹, Enrico VISMARA¹, Virginia BERLENGIERO² and Jérôme AVOUAC³, ¹Département de Rhumatologie, Hôpital Cochin, Assistance publique des Hôpitaux de Paris, Université Paris-Cité, Paris, France, PARIS, France, ²Rheumatoloy Department, Cochin Hospital, PARIS, France, ³Rheumatology department, Cochin hospital, Paris, France
Background/Purpose: Interstitial lung disease (ILD) is a severe complication of rheumatoid arthritis (RA), associated with increased morbidity and mortality. The pulmonary safety of biologic (bDMARDs)…
Abstract Number: 1353 • ACR Convergence 2025
Phase 3 Study of the Efficacy, Safety and Immunogenicity of the Proposed Tocilizumab Biosimilar RGB-19, Intravenously Administered to Participants With Active Rheumatoid Arthritis: 52-Week Data
Gerd Burmester¹, Hiroaki Matsuno², Ernest Choy³, Masato Okada⁴, Roshan Dias⁵, Károly Horvát-Karajz⁵, Gordana Dancer⁵, Yusuke Karibe⁶, Suguru Masuda⁶, Joachim Kiefer⁵ and Paul Emery⁷, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Matsuno Clinic for Rheumatic Disease, Toyama, and Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ³Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, ⁴Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁵Gedeon Richter Plc, Budapest, Hungary, ⁶Mochida Pharmaceutical Co., Ltd, Tokyo, Japan, ⁷University of Leeds, Leeds, England, United Kingdom
Background/Purpose: RGB-19 is a proposed biosimilar to tocilizumab, a monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor. Results of a…
Abstract Number: 1336 • ACR Convergence 2025
Effectiveness of new initiators of tofacitinib and other biologic/targeted synthetic DMARDs in patients with rheumatoid arthritis
Katherine Liao¹, Chandrasekar Gopalakrishnan², Jinoos Yazdany³, Griffith Bell⁴, Suraj Mothi⁵, Genevieve Gauthier⁶, Arne Yndestad⁷ and Milena Gianfrancesco⁸, ¹Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, MA, USA, Boston, MA, ²OM¹ Inc, Boston, MA, USA, Boston, ³UCSF, San Francisco, CA, ⁴Pfizer Inc, New York, NY, USA, Boston, MA, ⁵OM¹ Inc, Boston, MA, USA, Boston, MA, ⁶Pfizer Canada ULC, Kirkland, QC, Canada, Montreal, Canada, ⁷Pfizer Inc, Oslo, Norway, Oslo, Norway, ⁸Pfizer Inc, New York, NY, USA, New York, NY
Background/Purpose: Though the efficacy and safety profile of tofacitinib in RA has been established in prior trials, the effectiveness of tofacitinib in routine care settings…
Abstract Number: 1319 • ACR Convergence 2025
The Association of Rheumatoid Arthritis in Patients with Vitiligo: Systematic Review and Meta-Analysis
Nattanicha Chaisrimaneepan¹, thunyaporn Khoruamklang², Pitchaporn Yingchoncharoen³, Tulaton Sodsri⁴ and Miriam Paz³, ¹Texas Tech University Health Sciences Center, Lubbock, TX, ²²Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, bangkok, Thailand, ³Texas Tech University Health Sciences Center, Lubbock, ⁴Department of Medicine, Texas Tech University Health Sciences Center, Bangkok, Thailand
Background/Purpose: Vitiligo is associated with many autoimmune diseases, but its association with rheumatic disease has not been well-defined. Therefore, we conducted a systematic review and…
Abstract Number: 1266 • ACR Convergence 2025
Shared Decision Making in Rheumatoid Arthritis: Is RA disease activity associated with patient reported measures of shared decision making pre-SDM intervention?
Jennifer Barton¹, Joshua Baker², gabriela Schmajuk³, Madhavi Valiveti⁴, Alexandra Bennett⁵, Benjamin Morasco⁶, Allison O'Neill⁷ and Meike Niederhausen⁸, ¹VA Portland Health Care System/OHSU, Portland, OR, ²University of Pennsylvania, Philadelphia, PA, ³University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁴VAMC Wilmington, Wilmington, DE, ⁵Center to Improve Veteran Involvement in Care (CIVIC) and VA Portland Health Care System, Portland, OR, ⁶Center to Improve Veteran Involvement in Care, VA Portland Health Care System, Portland, OR, ⁷Center to Improve Veteran Involvement in Care, VA Portland Health Care System, Portland, OR, ⁸Oregon Health & Science University/VA Portland Health Care System, Portland, OR
Background/Purpose: Shared decision making (SDM) is outlined as the first overarching principle of the treat to target guidelines for rheumatoid arthritis (RA). The quality of…
Abstract Number: 1095 • ACR Convergence 2025
Tolerance of non-TNF α treatments in patient with an inflammatory rheumatic (IRD) and autoimmune demyelinating diseases: French retrospective cases series
dellal azeddine¹, Jean-Guillaume Letarouilly², Jacques Morel³, René-Marc Flipo⁴, Valerie Devauchelle⁵, richette pascal⁶, Philippe Dieude⁷, Hubert Marotte⁸, FELTEN Renaud⁹, LATOURTE Augustin¹⁰, CHEVET Baptiste¹¹, HILLIQUIN Pascal¹², SORDET Christelle⁹, DERNIS mmanuelle¹³, WENDLING Daniel¹⁴, Arsène Mekinian¹⁵, Nathalie BALLANDRAUD¹⁶, Christophe Richez¹⁷, TOURNADRE Anne¹⁸, salmon Jean -Hugues¹⁹, SAILLOT Carine²⁰, kedra joanna²¹, nahon stephane²², LE GOFF Benoit²³, Bruno Fautrel²⁴, Francis BERENBAUM²⁵, David SAADOUN²⁶, PHAM Thao¹⁶ and SELLAM JEREMIE²⁷, ¹GHI LE RAINCY MONTFERMEIL, Montfermeil, France, ²Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, LILLE, Nord-Pas-de-Calais, France, ³CHU and University of Montpellier, Montpellier, France, ⁴Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, Lille, France, ⁵UBO, Brest, France, ⁶Rheumatology Department, Lariboisiere Hospital, Paris, Ile-de-France, France, ⁷Service de Rhumatologie, Hôpital Bichat APHP, Paris, Paris, Ile-de-France, France, ⁸INSERM ¹⁰⁵⁹/University of Saint-Etienne, Saint-Etienne, France, ⁹Service de Rhumatologie, Centre de référence des maladies auto-immunes rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, Strasbourg, Alsace, France, ¹⁰Rheumatology Department, Lariboisiere Hospital, Paris, France, ¹¹CHU BREST, brest, Bretagne, France, ¹²CH SUD FRANCILIEN, PARIS, France, ¹³chu caen, CAEN, Haute-Normandie, France, ¹⁴CHU de Besançon, Besançon, Franche-Comte, France, ¹⁵Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ¹⁶CHU MARSEILLE, marseille, Provence-Alpes-Cote d'Azur, France, ¹⁷Bordeaux University Hospital, Bordeaux, France, ¹⁸CHU CLERMONT, CLERMONT, Lorraine, France, ¹⁹CHU REIMS, REIMS, Champagne-Ardenne, France, ²⁰CHU ORLEANS, ORLEANS, Pays de la Loire, France, ²¹Pitié-Salpêtrière Hospital, Rheumatology Department, APHP, Sorbonne University,, Paris, France, ²²GHI LE RAINCY MONTFERMEIL, Montfermeil, Ile-de-France, France, ²³CHU Nantes, Nantes, France, ²⁴Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France, ²⁵Sorbonne University/Inserm/AP-HP/⁴Moving Biotech, Paris, France, ²⁶CHU LA PITIE SALPETRIERE, PARIS, Ile-de-France, France, ²⁷Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-⁷⁵⁰¹² Paris, France, /Rheumatology Department, AP-HP Saint-Antoine Hospital, ¹⁸⁴, rue du Faubourg Saint-Antoine, ⁷⁵⁰¹², Paris, France., Paris, France
Background/Purpose: The use of TNFα antagonist is not recommended if the patient have a suspicion or demyelinating diseases (DD) confirmed [1]. There are a few…
Abstract Number: 1025 • ACR Convergence 2025
Association Between Rural-Urban Clinics and the Management of Adult Rheumatoid Arthritis in the United States
Megan Lorenz, Paxten Wahlund, Henry Elsenpeter, Abe Sahmoun and James Beal, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND
Background/Purpose: Disease modifying anti-rheumatic drugs (DMARDs) improve symptom management and outcomes in rheumatoid arthritis (RA). While residence may influence management strategies and access to care,…
Abstract Number: 0924 • ACR Convergence 2025
Human Serum Albumin Co-Modified with Malondialdehyde-Acetaldehyde and Citrulline Bind Multiple Scavenger Receptors and Alter Cellular Morphology
Lauren Klingemann¹, Michael Duryee¹, Nozima Aripova¹, Wenxian Zhou², Hannah Johnson¹, Breanna Butler¹, Carlos Hunter¹, Ted Mikuls¹ and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Bellevue, NE
Background/Purpose: Post-translational modifications (PTMs) of self-proteins are implicated in the pathogenesis of rheumatoid arthritis (RA). The PTMs, malondialdehyde-acetaldehyde (MAA), citrulline (CIT), and the co-modification of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].